Scarica l'app Stockscreener
10.85
0.37%
-0.04
Precedente Chiudi:
$10.89
Aprire:
$11.345
Volume 24 ore:
8,639
Relative Volume:
1.07
Capitalizzazione di mercato:
$103.39M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-3.21%
1M Prestazione:
+9.05%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$10.50
$11.65
Intervallo di 1 settimana:
$10.50
$11.96
Portata 52W:
$9.75
$22.63
Exozymes Inc Stock (EXOZ) Company Profile
Confronta EXOZ con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EXOZ
Exozymes Inc
|
10.85 | 103.39M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Exozymes Inc Borsa (EXOZ) Ultime notizie
BioClick – an enzyme engineering game-changer, launched by eXoZymes and supported by a $300K NIH grant - ADVFN
eXoZymes creates AI-engineered enzymes for biomanufacturing - Scientific Computing World
eXoZymes Inc. Introduces 'Exozymes' Terminology in Cover Story of GEN Biotechnology to Advance Cell-Free Biomanufacturing - Nasdaq
Bringing clarity and precision to the cell-free space by introducing exozymes | Daily Guardian - dailyguardian.ca
Bringing clarity and precision to the cell-free space by introducing exozymes - GlobeNewswire
Press Release Distribution & PR Platform - ACCESS Newswire
New to The Street Announces Bloomberg Television Lineup for Saturday, April 12 at 6:30 PM ET Featuring Health In Tech CEO Julia Qian, BIOVie’s Dr. Joe Palumbo, The Sustainable Green Team with Kevin Harrington and Tony Raynor, and eXoZymes Vice - Yahoo Finance
New to The Street Announces Bloomberg Television Lineup for Saturday, April 12 at 6:30 PM ET Featuring Health In Tech CEO Julia Qian, BioVie's Dr. Joseph Palumbo, The Sustainable Green Team with Kevin Harrington and Tony Raynor, and eXoZymes Vic - ACCESS Newswire
EXoZymes Inc. Announces Its Latest Initiative BioClick - MarketScreener
Game-Changing BioClick Platform Secures NIH Grant for Next-Gen Drug Development - Stock Titan
eXoZymes appoints Damien Perriman as Chief Commercial Officer - World Bio Market Insights
eXoZymes Inc. Reports 2024 Progress and IPO Success - TipRanks
eXoZymes Provides Fourth Quarter and Full Year 2024 Update - GlobeNewswire
eXoZymes appoints new chief commercial officer By Investing.com - Investing.com Canada
eXoZymes appoints new chief commercial officer - Investing.com
eXoZymes appoints experienced biomanufacturing executive, Damien Perriman, as CCO - GlobeNewswire
Strategic Win: eXoZymes Taps 20-Year Biotech Leader to Drive Commercial Growth - Stock Titan
MDB Capital's Remarkable Growth: AUM Soars 2100%, New Platform Launch Drives Expansion - Stock Titan
eXoZymes Inc. (EXOZ) reports earnings - qz.com
New to The Street Show #639 Premieres Nationwide on Bloomberg Television, March 29 at 6:30 PM EST Featuring BioVie, Roadzen, Tonix Pharma, and eXoZymes Inc. - ACCESS Newswire
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
eXoZymes to Host Fourth Quarter and Full Year 2024 Results Conference Call on Wednesday April 2, 2025 - GlobeNewswire
AI Enzyme Pioneer EXOZ Reveals 2024 Financial Performance: Q4 Earnings Call Details - Stock Titan
New to The Street’s FOX Business Show #638 Spotlights Visionary CEOs and Breakthrough Innovations Across Health, AI, and Insurance Featuring BioVie CEO Cuong Do, Roadzen CEO Rohan Malhotra, Lou Basenese’s The Big Skinny on eXoZymes, and B - The State
New to The Street's FOX Business Show #638 Spotlights Visionary CEOs and Breakthrough Innovations Across Health, AI, and Insurance Featuring BioVie CEO Cuong Do, Roadzen CEO Rohan Malhotra, Lou Basenese's The Big Skinny on eXoZymes, and B - ACCESS Newswire
MDB Capital's 2024 Financial Results: CEO to Reveal Full Year Performance and Strategic Outlook - StockTitan
Who's Winning the AI Data Center Patent Race? New Report Reveals Surprising Leader - StockTitan
New to the Street Airs Show #630 on Fox Business Network Tonight at 10:30 PM PST Featuring Roadzen ($RDZN), BioVie ($BIVI), AtlasClear (ATCH), eXoZymes ($EXOZ), and EvolveHealthandLifestyle. - Markets Insider
New to the Street Airs Show #630 on Fox Business Network Tonight at 10:30 PM PST Featuring Roadzen ($RDZN), BioVie ($BIVI), AtlasClear (ATCH), eXoZymes ($EXOZ), and EvolveHealthandLifestyle.com With Craig Bruce - Corsicana Daily Sun
New to the Street Airs Show #630 on Fox Business Network Tonight at 10:30 PM PST Featuring Roadzen ($RDZN), BioVie ($BIVI), AtlasClear (ATCH), eXoZymes ($EXOZ), and EvolveHealthandLifestyle.com With C - StreetInsider
eXoZymes president, chairman Hayat transitions out of roles - MSN
EXoZymes, Inc. Announces Management Changes -February 21, 2025 at 04:37 pm EST - Marketscreener.com
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
ExoZymes Inc. appoints new board member and chairman By Investing.com - Investing.com Nigeria
eXoZymes Announces Leadership Changes with New Appointments - TipRanks
eXoZymes and MDB Capital Announce Leadership Transition at - GlobeNewswire
ExoZymes Inc. appoints new board member and chairman - Investing.com
eXoZymes Inc. Announces Leadership Changes and Rebranding Following Transition from Invizyne Technologies - Nasdaq
eXoZymes and MDB Capital Announce Leadership Transition at eXoZymes Inc. - GlobeNewswire
Exozymes (EXOZ) Income Statement & Balance Sheet 2025 - MarketBeat
eXoZymes Inc Rings the Nasdaq Stock Market Closing Bell - Nasdaq
eXoZymes Inc Rings the Closing Bell - Nasdaq
Reynolds Consumer Products, Inc Rings the Nasdaq Stock Market Opening Bell - Nasdaq
Biotech’s New Frontier: Discover the “Exozymes Era” Revolutionizing Chemical Production - Mi Valle
Exozymes Inc Azioni (EXOZ) Dati Finanziari
Non sono disponibili dati finanziari per Exozymes Inc (EXOZ). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
0.39%
3.66%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):